Global Lubiprostone Market Projected to Reach USD 1.78 Billion by 2034, Growing at a CAGR of 5.8%; Key Trends and Competitive Landscape According to a new report from Intel Market Research,Global Lubiprostone market was valued at USD 1.05 billion in 2026 and is projected to reach USD 1.78 billion by 2034, growing at a steady CAGR of 5.8% during the forecast period. This growth is driven by rising prevalence of chronic gastrointestinal disorders, increasing opioid-induced constipation cases, and expanding therapeutic applications in gastroenterology. What is Lubiprostone? Lubiprostone (marketed as Amitiza® and generics) is a selective chloride channel activator that enhances intestinal fluid secretion without altering sodium/water absorption. This unique mechanism positions it as a first-line therapy for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in women. Unlike traditional osmotic laxatives, it addresses the root pathophysiology by activating type 2 chloride channels in gut epithelial cells, leading to softer stools and improved bowel motility. This comprehensive report delivers critical insights into the Lubiprostone market landscape, analyzing macro trends and micro-details encompassing market sizing, competitive intelligence, technological advancements, regulatory developments, and strategic opportunities across 18 key countries. Download FREE Sample Report: https://www.intelmarketresearch.com/download-free-sample/34955/lubiprostone-market Download FREE Sample Report: Lubiprostone Market - View in Detailed Research Report